Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, recently celebrated the continued growth of its U.S. manufacturing site in Milford, MA, marking significant progress following the company’s major expansion in the region. Since establishing the facility in 2019, the site has evolved into a state-of-the-art, multi-product manufacturing hub supporting biopharmaceutical development and commercial supply.
“Milford is our cornerstone for Rentschler Biopharma’s global growth plans because of the proximity to our customers and the world’s great innovators,” said Uwe Buecheler, Interim CEO.
The event highlighted the site’s milestones and its growing role within the company’s global network. Local legislative leaders and members of the life sciences ecosystem joined the celebration, recognizing the company’s contributions to the region’s biotechnology industry and local economy.
“Other regions of the world are turning inward, but growth requires building bridges. We believe in the direction we are heading, and in the people here in Massachusetts,” said Nikolaus F. Rentschler, Chairman of the Supervisory Board.
A new production line, which became fully operational in 2024 as part of the company’s largest expansion in its more than 150-year history, added 22,000 square feet of manufacturing cleanroom space, which significantly expanded the company’s global cGMP capacity, and houses four 2,000 L single-use bioreactors. The facility supports a diverse pipeline of therapeutics spanning multiple disease areas, including oncology, hematology, cardiovascular disease, and organ failure.
Rentschler Biopharma is a two-time awardee of the MLSC’s Tax Incentive program.
